Vericel Price to Earnings Ratio from 2010 to 2024
| VCEL Stock | USD 57.76 0.99 1.69% |
Check Vericel Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vericel Corp's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.9 M, Interest Expense of 630 K or Total Revenue of 207.4 M, as well as many indicators such as Price To Sales Ratio of 8.15, Dividend Yield of 0.0 or PTB Ratio of 3.9. Vericel financial statements analysis is a perfect complement when working with Vericel Corp Valuation or Volatility modules.
Vericel | Price to Earnings Ratio |
About Vericel Corp Financial Statements
Vericel Corp investors utilize fundamental indicators, such as Price to Earnings Ratio, to predict how Vericel Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. Vericel operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 281 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Vericel Corp Correlation against competitors. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vericel Corp. If investors know Vericel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vericel Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.045 | Earnings Share 0.08 | Revenue Per Share 4.685 | Quarterly Revenue Growth 0.27 | Return On Assets (0) |
The market value of Vericel Corp Ord is measured differently than its book value, which is the value of Vericel that is recorded on the company's balance sheet. Investors also form their own opinion of Vericel Corp's value that differs from its market value or its book value, called intrinsic value, which is Vericel Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vericel Corp's market value can be influenced by many factors that don't directly affect Vericel Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vericel Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vericel Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vericel Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.